414 related articles for article (PubMed ID: 32265933)
21. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
22. Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy.
Song Y; Li Z; Xue W; Zhang M
Immunotherapy; 2019 Apr; 11(6):515-529. PubMed ID: 30860441
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
Terranova-Barberio M; Thomas S; Munster PN
Immunotherapy; 2016 Jun; 8(6):705-19. PubMed ID: 27197539
[TBL] [Abstract][Full Text] [Related]
24. Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.
Qi J; Jin F; Xu X; Du Y
Int J Nanomedicine; 2021; 16():1435-1456. PubMed ID: 33654395
[TBL] [Abstract][Full Text] [Related]
25. Hyperprogressive Disease: Main Features and Key Controversies.
Arasanz H; Zuazo M; Bocanegra A; Chocarro L; Blanco E; Martínez M; Morilla I; Fernández G; Teijeira L; Morente P; Echaide M; Castro N; Fernández L; Garnica M; Ramos P; Escors D; Kochan G; Vera R
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916696
[TBL] [Abstract][Full Text] [Related]
26. Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.
Melissaropoulos K; Klavdianou K; Filippopoulou A; Kalofonou F; Kalofonos H; Daoussis D
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32403289
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive Immune Monitoring of Clinical Trials to Advance Human Immunotherapy.
Hartmann FJ; Babdor J; Gherardini PF; Amir ED; Jones K; Sahaf B; Marquez DM; Krutzik P; O'Donnell E; Sigal N; Maecker HT; Meyer E; Spitzer MH; Bendall SC
Cell Rep; 2019 Jul; 28(3):819-831.e4. PubMed ID: 31315057
[TBL] [Abstract][Full Text] [Related]
28. Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients.
Pirozyan MR; McGuire HM; Emran AA; Tseng HY; Tiffen JC; Lee JH; Carlino MS; Menzies AM; Long GV; Scolyer RA; Fazekas de St Groth B; Hersey P
Front Immunol; 2020; 11():372. PubMed ID: 32210968
[TBL] [Abstract][Full Text] [Related]
29. Cancer, obesity and immunometabolism - Connecting the dots.
Dyck L; Lynch L
Cancer Lett; 2018 Mar; 417():11-20. PubMed ID: 29253522
[No Abstract] [Full Text] [Related]
30. Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies.
Hernandez C; Arasanz H; Chocarro L; Bocanegra A; Zuazo M; Fernandez-Hinojal G; Blanco E; Vera R; Escors D; Kochan G
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244396
[TBL] [Abstract][Full Text] [Related]
31. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
Zhu MMT; Shenasa E; Nielsen TO
Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422
[TBL] [Abstract][Full Text] [Related]
32. Conference scene: Immune signatures in the tumor and beyond.
Kandalaft LE; Kalos M; Melief CJ; Speiser DE; Coukos G
Immunotherapy; 2012 Aug; 4(8):761-72. PubMed ID: 22947003
[TBL] [Abstract][Full Text] [Related]
33. Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis.
Heinrich S; Craig AJ; Ma L; Heinrich B; Greten TF; Wang XW
J Hepatol; 2021 Mar; 74(3):700-715. PubMed ID: 33271159
[TBL] [Abstract][Full Text] [Related]
34. A digital single-molecule nanopillar SERS platform for predicting and monitoring immune toxicities in immunotherapy.
Li J; Wuethrich A; Sina AAI; Cheng HH; Wang Y; Behren A; Mainwaring PN; Trau M
Nat Commun; 2021 Feb; 12(1):1087. PubMed ID: 33597530
[TBL] [Abstract][Full Text] [Related]
35. Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy.
Pérez-Romero K; Rodríguez RM; Amedei A; Barceló-Coblijn G; Lopez DH
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32752264
[TBL] [Abstract][Full Text] [Related]
36. Tackling Resistance to Cancer Immunotherapy: What Do We Know?
Gondhowiardjo SA; Handoko ; Jayalie VF; Apriantoni R; Barata AR; Senoaji F; Utami IJW; Maubere F; Nuryadi E; Giselvania A
Molecules; 2020 Sep; 25(18):. PubMed ID: 32911646
[TBL] [Abstract][Full Text] [Related]
37. NK Cell-Based Immune Checkpoint Inhibition.
Khan M; Arooj S; Wang H
Front Immunol; 2020; 11():167. PubMed ID: 32117298
[TBL] [Abstract][Full Text] [Related]
38. The effect of patient sex on the efficacy and safety of anticancer immunotherapy.
Pala L; Conforti F
Expert Opin Drug Saf; 2021 Dec; 20(12):1535-1544. PubMed ID: 34468257
[No Abstract] [Full Text] [Related]
39. Biomarkers of related driver genes predict anti-tumor efficacy of immune checkpoint inhibitors.
Jiang S; Geng S; Luo X; Zhang C; Yu Y; Cheng M; Zhang S; Shi N; Dong M
Front Immunol; 2022; 13():995785. PubMed ID: 36189266
[TBL] [Abstract][Full Text] [Related]
40. Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3.
Hayakawa T; Yaguchi T; Kawakami Y
Cancer Sci; 2020 Dec; 111(12):4326-4335. PubMed ID: 33006786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
